quantisnow
FeedTopReportsPricing
⌘K
Live feed
11:50:28·29d
PRRelease
Denali Therapeutics Inc. logo

Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)

DNLI· Denali Therapeutics Inc.
Health Care
Original source

Companies

  • DNLI
    Denali Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Mar 26UpdateH.C. Wainwright$42.00
  • Feb 24UpdateWolfe Research-
  • Jan 7UpdateUBS$25.00
  • Apr 10UpdateCantor Fitzgerald-
  • Mar 7UpdateMorgan Stanley$33.00
  • Feb 11UpdateDeutsche Bank$31.00

Related

  • INSIDER2d
    Amendment: SEC Form 3 filed by new insider Chin Peter Scott
  • SEC2d
    SEC Form DEFA14A filed by Denali Therapeutics Inc.
  • SEC2d
    SEC Form DEF 14A filed by Denali Therapeutics Inc.
  • INSIDER3d
    SEC Form 3 filed by new insider Chin Peter Scott
  • PR3d
    When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
  • SEC20d
    Denali Therapeutics Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Financial Statements and Exhibits
  • PR20d
    Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)
  • SEC23d
    Denali Therapeutics Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement, Regulation FD Disclosure
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022